- Home
- MUR vs RNA Comparison
MUR vs RNA Comparison
Compare MUR & RNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MUR
- RNA
- Stock Information
- Founded
- MUR 1950
- RNA 2012
- Country
- MUR United States
- RNA United States
- Employees
- MUR N/A
- RNA N/A
- Industry
- MUR Oil & Gas Production
- RNA Biotechnology: Pharmaceutical Preparations
- Sector
- MUR Energy
- RNA Health Care
- Exchange
- MUR Nasdaq
- RNA Nasdaq
- Market Cap
- MUR 3.7B
- RNA 4.0B
- IPO Year
- MUR N/A
- RNA 2020
- Fundamental
- Price
- MUR $26.92
- RNA $40.06
- Analyst Decision
- MUR Hold
- RNA Strong Buy
- Analyst Count
- MUR 15
- RNA 16
- Target Price
- MUR $28.69
- RNA $69.81
- AVG Volume (30 Days)
- MUR 2.2M
- RNA 3.7M
- Earning Date
- MUR 11-06-2025
- RNA 11-06-2025
- Dividend Yield
- MUR 4.80%
- RNA N/A
- EPS Growth
- MUR N/A
- RNA N/A
- EPS
- MUR 1.95
- RNA N/A
- Revenue
- MUR $2,779,887,000.00
- RNA $10,729,000.00
- Revenue This Year
- MUR N/A
- RNA N/A
- Revenue Next Year
- MUR $4.10
- RNA $109.60
- P/E Ratio
- MUR $13.87
- RNA N/A
- Revenue Growth
- MUR N/A
- RNA 1.23
- 52 Week Low
- MUR $18.95
- RNA $21.51
- 52 Week High
- MUR $36.63
- RNA $56.00
- Technical
- Relative Strength Index (RSI)
- MUR 61.30
- RNA 41.60
- Support Level
- MUR $25.32
- RNA $39.83
- Resistance Level
- MUR $28.00
- RNA $46.23
- Average True Range (ATR)
- MUR 0.98
- RNA 2.92
- MACD
- MUR 0.24
- RNA -1.24
- Stochastic Oscillator
- MUR 70.73
- RNA 27.77
About MUR Murphy Oil Corporation
Murphy Oil Corp is an oil and gas exploration and production company, with both onshore and offshore operations and properties. It operates in two geographic reportable segments the United States and Canada. It generates the majority of its revenue form the United States.
About RNA Avidity Biosciences Inc.
Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD.